Patent ID: 9289466
Filing Date: 2016-03-22
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of treating a pathological condition in a mammal including a human, the method comprising: administering to a mammal in need of such treatment an effective amount of a recombinant binding protein comprising an ankyrin repeat domain and a polyethylene glycol moiety, wherein the ankyrin repeat domain binds vascular endothelial growth factor-A165 (VEGF-A165) and inhibits VEGF-A165 binding to vascular endothelial growth factor receptor-2 (VEGFR-2), and wherein the ankyrin repeat domain comprises an amino acid sequence selected from the group consisting of amino acids 1 to 159 of SEQ ID NO:1, amino acids 1 to 159 of SEQ ID NO:2, amino acids 1 to 126 of SEQ ID NO:3, amino acids 1 to 126 of SEQ ID NO:4, amino acids 1 to 126 of SEQ ID NO:5, amino acids 1 to 126 of SEQ ID NO:6, and amino acids 1 to 159 of SEQ ID NO:7, and wherein the polyethylene glycol moiety has a molecular weight of about 2 kDa to about 100 kDa, and wherein the pathological condition is wet macular degeneration, diabetic macular edema, diabetic retinopathy, central retinal vein occlusion, stenosis of the carotid artery, sickle cell retinopathy, renal cell carcinoma, hepatocellular carcinoma, or colorectal cancer.